Evaluating Impurities in Drugs (Part II of III) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Impurities in Drugs (Part II of III)
In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 58-72

60. D.P. Kjell et al., Org. Proc. Res. Dev. 9 (6), 738–742, 2005.

61. K. Kassahun et al., Drug Metab. Dispos. 25 (1), 81–93 (1997).

62. K. Kassahun et al., Drug Metab. Dispos. 26 (9), 848–855 (1998).

63. E. Mattiuz et al., Drug Metab. Dispos. 25 (1), 573–583(1997).

64. M. Lalitha Devi et al., J. Pharm. Biomed. Anal. 50 (5), 710–717 (2009).

65. Y. Yoshida et al., Arzneimittelforschung 43 (5), 601–606 (1993).

66. J. Sunderlanda et al., J. Antimicrob. Chemother. 47 (3), 271–275 (2001).

67. A. V. Polishchuk et al., High Energy Chemistry 42 (6), 459–463 (2008).

68. W. Gau, et al., Arzneimittel Forschung 36 (10), 1545–1549 (1986).

69. P. Mojaverian et al., J. Pharm. Biomed. Anal. 16 (3), 439–445 (1997).

70. A. Taicheng et al., Applied Catalysis B: Environmental 94 (3–4), 288–294, 2010.

71. M. Mella et al., Helvetica Chimica Acta 84 (8), 2508–2519 (2001).

72. K.A. Thabaj et al., Polyhedron 26 (17), 4877–4885 (2007).

73. T.G. Vasconcelos et al., Chemosphere 76 (4), 487–493 (2009).

74. K. Torniainen et al., J. Pharm. Biomed. Anal. 15 (7), 887–894 (1997).

75. K. Tovarna Zdravil, "Process for Preparing Purified Ciprofloxacin," WO 2005/075430, Aug. 2005.

76. R. J. Islam M et al., J. Pharm. Sci. 90 (5), 541–544 (2001).

77. H.V Hogerzeil et al., British Medical Journal 304, 210–214 (1992).

78. R. J. Bhuiyan K et al., Indian Drugs 34 (11), 634-636 (1997).

79. EMA, Guideline on the Limits of Genotoxic Impurities (London, June, 2006).

80. B.N. Ames and L.S. Gold, Proc. Nat. Acad. Sci. USA 87 (19), 7772–7776 (1990).

81. B.N. Ames and L.S. Gold, Proc. Nat. Acad. Sci. USA 87 (19), 7777- 7781 (1990).

82. M.A. Cheeseman et al., Food Chain Toxicol. 37, 387–412 (1999).

83. D.A. Pierson et al., Org. Proc. Res. Dev. 13 (2), 285–291 (2009).

84. D.P. Elder. et al., J. Pharm. Biomed. Anal. 48 (3), 497–507 (2008).

85. D.P. Elder. et al., J. Pharm. Biomed. Anal. 46 (1), 1–8 (2008).

86. D.P. Elder. et al., J. Pharm. Sci. 99 (7,) 2948-2961 (2010).

87. G.E. Taylor. et al., J. Chromatogr A 1119 (1–2), 231–237 (2006).

88. K. Ramakrishna. et al., J. Pharm. Biomed. Anal. 46 (4), 780–783 (2008).

89. N.V.V.S.S. Raman. et al., J. Pharm. Biomed. Anal. 48 (1), 227–230 (2008).

90. J. G. Slatter et al., Drug Metab. Dispos. 29 (8), 1136–1145 (2001).

91. N. Plock et al., Drug Metab. Dispos. l35 (10), 1816–1823 (2007).

92. Wynalda et al., Drug Metab. Dispos. 28 (9), 1014–1017 ( 2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here